Agilent Technologies (A) Showcases NovoStation, Is The Stock Still Undervalued?
Agilent Technologies (A) just used the ICCS 2026 conference in Miami to showcase its NovoStation Sample Preparation System, tying a fresh automation launch directly to a specialist clinical cytometry audience.
Recent product launches like NovoStation and the BioTek Gen5 AI cell identification module come alongside a strong performance for Agilent Technologies, with the share price showing a 12.08% 1 month return and a 26.57% 3 month share price gain. The 1 year total shareholder return of 20.98% and 3 year total shareholder return of 52.50% indicate momentum that has been building rather than fading.
Scan beyond Agilent Technologies and see how other lab automation and life science tools stocks stack up in our hand-picked 88 robotics and automation stocks for this theme.
After a 26.57% move in three months and a 52.50% 3 year total shareholder return, the question around Agilent Technologies now shifts. Is most of the upside already in the rear-view mirror, or do the current valuation markers still leave room ahead?
Most Popular Narrative: 3% Undervalued
The most followed storyline on Agilent Technologies pegs fair value at $175.20, slightly above the last close at $169.09. This keeps the focus on how durable its margin and cash flow drivers really are.
The Ignite operating model continues to roll through Agilent Technologies, with management now attributing more than 100 basis points of expected FY26 operating margin expansion and about 200 basis points of strategic pricing benefit per quarter to this system. This can support net margin and EPS growth if it keeps offsetting inflation, tariffs and new capacity ramp costs.
See why 36 investors see Agilent Technologies as 3% undervalued.
Result: Fair Value of $175.20 (UNDERVALUED)
Still, if tariffs flare up again or the NASD Train C ramp takes longer than expected, the bullish Agilent Technologies story could quickly look stretched.
Find out about the key risks to this Agilent Technologies narrative.
Next Steps
Feeling optimistic about Agilent Technologies but not sure it lines up with your own risk tolerance and return expectations? Act quickly and pressure test the bullish case against the 3 key rewards.
Looking for more Agilent Technologies style investment ideas?
If Agilent Technologies has sharpened your focus on quality opportunities, use this moment to line up your next ideas before the market moves first.
- Target value with discipline and scan a curated 29 high quality undervalued stocks that pairs quality fundamentals with prices that may sit below intrinsic estimates.
- Prioritise resilience and review a list of solid balance sheet and fundamentals (25 results) that filters for companies with stronger financial footing and less stretched leverage.
- Get ahead of the crowd and comb through a 20 high quality undiscovered gems built to surface lesser known businesses with robust underlying metrics.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com